ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2872

Risk of 30-day Readmission and Adverse Events After Primary Hip or Knee Arthroplasty: A Comparison of Patients with Rheumatoid Arthritis versus Osteoarthritis Using the Nationwide Readmission Database

Ali Yazdanyar1, Anthony Donato 2, Kathleen McElwee 3, Mary Chester Wasko 4 and Michael Ward 5, 1Lehigh Valley Hospital- Cedar Crest, Allentown, PA, 2Reading Hospital, PA, Reading, 3Reading Hospital, Reading, PA, 4Allegheny Health Network-West Penn Hospital, Pittsburgh, PA, 5NIAMS, Bethesda, MD

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: joint arthroplasty and risk, outcomes, Rheumatoid arthritis (RA), surgery

  • Tweet
  • Email
  • Print
Session Information

Date: Wednesday, November 13, 2019

Title: 6W011: RA – Diagnosis, Manifestations, & Outcomes V: Treatment (2870–2875)

Session Type: ACR Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose: To assess the risk of 30-day readmission, mortality, and adverse events among adults with Rheumatoid Arthritis as compared to Osteoarthritis after primary hip or knee arthroplasty.

Methods: We identified index hospitalizations with a principal procedure of primary HA or KA using a nationally representative U.S. sample, the Nationwide Readmission Database (2010-2013).  Excluded were persons aged < 18 years or who did not survive the index hospitalization. The principal procedure and diagnoses were identified using ICD-9 codes. Using survey logistic regression, we calculated the unadjusted and adjusted risk of 30-day readmission, all-cause mortality, and composite adverse events which included infections, cardiovascular events, venous thromboembolic events, mechanical complications, and AKI, after adjusting for age, sex, and major comorbidities.

Results: There were 1,977,214 index hospitalizations of which 10,802 were in persons with RA and 1,966,413 in persons with OA.  Persons with RA were older (66.9 vs. 65.6; P< 0.01), more likely to be women (80.7% vs. 59.5%; P< 0.01), and to have existing comorbid conditions of CAD (10.0% vs. 8.0%;P< 0.01), chronic CHF (2.4% vs. 0.6%;P< 0.01 ), CKD (6.6% vs. 3.8%; P< 0.01), cancer (1.6% vs. 0.9%; P< 0.01), PVD (3.1% vs. 1.4%; P< 0.01), and COPD (20.8% vs. 14.0%; P< 0.01).  There were 68,897 (3.5%) 30-day readmissions. The readmission rate was higher among persons with RA compared to OA (7.1% vs. 3.5%; P< 0.001).  Stratified readmission rates for RA versus OA were (9.3% vs. 3.4%; P< 0.001) and (4.2% vs. 3.5%; P=0.18) in HA and KA, respectively.   The adjusted OR for readmission was 2.06 [ 95% CI: 1.75,2.42], all-cause mortality 9.87 [95% CI:5.02,19.41], and composite event 2.29 [95% CI:1.81,2.89].  In analyses stratified by procedure type, the adjusted OR post-HA for readmission was 2.35 [ 95% CI: 1.94,2.83], all-cause mortality 6.16 [95% CI:2.96,12.82], and composite event 2.32 [95% CI:1.79,2.99] while post-KA the risk of readmission was 1.36 [ 95% CI: 1.02,1.80], all-cause mortality 13.81 [95% CI:3.35,56.90], and 1.78 for composite event [95% CI:1.14,2.78].  The overall adjusted risk for mechanical complications [OR:4.38; 95% CI:2.56,7.47], all-type infections [OR:2.23; 95% CI:1.71,2.92], and AKI [OR:3.78; 95% CI:1.41,10.13]  was higher in RA while the risk for CVD [OR:1.73; 95% CI:0.77,3.87], DVT/PE [OR:0.95; 95% CI:0.45,2.02], or surgical site infections [OR:1.51; 95% CI:0.98,2.31] did not differ relative to OA.  In stratified analyses, the risk for AKI and all-type infections was higher among persons RA in both procedure types while the risk for mechanical complications was only significant in HA [OR:1.99; 95% CI:1.14,3.47].

Conclusion: After primary joint arthroplasty, the 30-day rehospitalization, all-cause mortality, and composite events were more likely among persons with RA relative to OA, even after accounting for demographics and major co-morbidities.  All-type infections and acute kidney injury were more likely among person with RA after both hip and knee arthroplasty, while mechanical complication was significantly higher in persons with RA as compared to OA only after hip arthroplasty.


Table of Abbreviations


Disclosure: A. Yazdanyar, None; A. Donato, None; K. McElwee, None; M. Wasko, None; M. Ward, None.

To cite this abstract in AMA style:

Yazdanyar A, Donato A, McElwee K, Wasko M, Ward M. Risk of 30-day Readmission and Adverse Events After Primary Hip or Knee Arthroplasty: A Comparison of Patients with Rheumatoid Arthritis versus Osteoarthritis Using the Nationwide Readmission Database [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/risk-of-30-day-readmission-and-adverse-events-after-primary-hip-or-knee-arthroplasty-a-comparison-of-patients-with-rheumatoid-arthritis-versus-osteoarthritis-using-the-nationwide-readmission-database/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-of-30-day-readmission-and-adverse-events-after-primary-hip-or-knee-arthroplasty-a-comparison-of-patients-with-rheumatoid-arthritis-versus-osteoarthritis-using-the-nationwide-readmission-database/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology